Last reviewed · How we verify
NCT04881916
Immune and Genomic Markers in ALK+ NSCLC
trial in Anaplastic Lymphoma Kinase Gene Translocation in 100 participants. Participants enrolled and being followed up; not accepting new ones.
1 July 2027
Quick facts
| Lead sponsor | Massachusetts General Hospital |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 1 December 2021 |
| Primary completion | 1 July 2027 |
| Estimated completion | 1 July 2027 |
| Sites | 1 location across United States |
Conditions studied
- Anaplastic Lymphoma Kinase Gene Translocation — all drugs for Anaplastic Lymphoma Kinase Gene Translocation →
- Non-Small Cell Lung Cancer — all drugs for Non-Small Cell Lung Cancer →
Sponsor
Massachusetts General Hospital
Who can join
18 and older, any sex, with Anaplastic Lymphoma Kinase Gene Translocation or Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this research study is to obtain and study clinical history, and tissue and saliva specimens if available from participants with Anaplastic Lymphoma Kinase-ALK+ Non-Small Lung Cancer(NSCLC)
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
ALK-positive lung cancer: a moving target.
Schneider JL, Lin JJ, Shaw AT. · · 2023 · cited 131× · PMID 36797503 · DOI 10.1038/s43018-023-00515-0 -
ENIGMA+: a national, decentralized, remote consent study for clinical data and biospecimen collection in patients with ALK-positive advanced NSCLC.
Liang J, Waliany S, Do A, Peterson JL, et al · · 2025 · PMID 40674592 · DOI 10.1093/oncolo/oyaf217
Verify or expand the search:
- PubMed search for NCT04881916
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Anaplastic Lymphoma Kinase Gene Translocation
Currently open trials in the same condition.
- NCT05525338 — Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels · Phase 4 · recruiting
Other Massachusetts General Hospital trials
Trials by the same sponsor.
- NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
- NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
- NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
- NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
- NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04881916 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
- Last refreshed: 30 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04881916.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing